Clinical Trial Update: Safety and Tolerability of HepaStem in Patients With Cirrhotic and Pre-cirrhotic NASH Patients [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial updates on HepaStem show safety and tolerability in patients with cirrhotic and pre-cirrhotic nonalcoholic steatohepatitis (NASH).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis
• Nonalcoholic Steatohepatitis

Drugs mentioned

• HepaStem

Snippet

Sponsor: Cellaion SA | Conditions: NASH - Nonalcoholic Steatohepatitis | Phase 1, Phase 2 | Status: COMPLETED